Combining conventional immune checkpoint inhibition of CTLA‐4 and PD‐1 may enhance the Treg depletion within the tumor and further potentiate the CD4+ and CD8+ antitumor immunity (Table 1). The gene discussed is CD8A; the disease is neoplasm.